The stock price of Seres Therapeutics Inc. (NASDAQ: MCRB) has plunged by -3.85 when compared to previous closing price of 2.86, but the company has seen a -10.42% decline in its stock price over the last five trading sessions. Seeking Alpha reported 2023-09-01 that Seres Therapeutics trades near its 52-week low and presents an asymmetric risk-reward profile. The company’s lead asset, SER-109, has successfully concluded its Phase III clinical trial for recurrent Clostridioides difficile infection. Seres Therapeutics’ partnership with Nestle provides financial backing and distribution support, highlighting the potential of its drug VOWST.
Is It Worth Investing in Seres Therapeutics Inc. (NASDAQ: MCRB) Right Now?
Moreover, the 36-month beta value for MCRB is 2.63. Analysts have varying opinions on the stock, with 5 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 1 as “sell.”
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
The average price recommended by analysts for Seres Therapeutics Inc. (MCRB) is $9.83, which is $7.08 above the current market price. The public float for MCRB is 119.52M and currently, short sellers hold a 16.93% of that float. On September 19, 2023, MCRB’s average trading volume was 2.33M shares.
MCRB’s Market Performance
MCRB stock saw a decrease of -10.42% in the past week, with a monthly decline of -21.43% and a quarterly a decrease of -48.88%. The volatility ratio for the week is 5.59%, and the volatility levels for the last 30 days are 5.04% for Seres Therapeutics Inc. (MCRB). The simple moving average for the past 20 days is -18.05% for MCRB’s stock, with a -46.40% simple moving average for the past 200 days.
Analysts’ Opinion of MCRB
Many brokerage firms have already submitted their reports for MCRB stocks, with Oppenheimer repeating the rating for MCRB by listing it as a “Outperform.” The predicted price for MCRB in the upcoming period, according to Oppenheimer is $12 based on the research report published on June 26, 2023 of the current year 2023.
MCRB Trading at -31.49% from the 50-Day Moving Average
After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -71.02% of loss for the given period.
Volatility was left at 5.04%, however, over the last 30 days, the volatility rate increased by 5.59%, as shares sank -22.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -42.23% lower at present.
During the last 5 trading sessions, MCRB fell by -10.42%, which changed the moving average for the period of 200-days by -58.65% in comparison to the 20-day moving average, which settled at $3.32. In addition, Seres Therapeutics Inc. saw -50.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MCRB starting from Ege David S., who sale 7,038 shares at the price of $5.19 back on Apr 28. After this action, Ege David S. now owns 59,696 shares of Seres Therapeutics Inc., valued at $36,527 using the latest closing price.
Ege David S., the of Seres Therapeutics Inc., sale 5,012 shares at $7.93 during a trade that took place back on Oct 31, which means that Ege David S. is holding 46,734 shares at $39,745 based on the most recent closing price.
Stock Fundamentals for MCRB
Current profitability levels for the company are sitting at:
- -3443.97 for the present operating margin
- -66.29 for the gross margin
The net margin for Seres Therapeutics Inc. stands at -3509.50. The total capital return value is set at -138.66, while invested capital returns managed to touch -145.68.
Based on Seres Therapeutics Inc. (MCRB), the company’s capital structure generated 1,507.84 points at debt to equity in total, while total debt to capital is 93.78. Total debt to assets is 46.62, with long-term debt to equity ratio resting at 1,470.21. Finally, the long-term debt to capital ratio is 91.44.
When we switch over and look at the enterprise to sales, we see a ratio of 2.67, with the company’s debt to enterprise value settled at 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.28.
Conclusion
To wrap up, the performance of Seres Therapeutics Inc. (MCRB) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
